



Large Chinese Biotech & Pharmaceutical group acquires 8% of Theraclion shares, as part of a private placement with institutional investors

Malakoff – May 2, 2016 – THERACLION (Alternext, FR0010120402 – ALTHE), a company specialized in leading-edge medical equipment for echotherapy, announced today that it has raised €1.8 million in a private placement with institutional investors. The transaction was completed in accordance with Article L. 411-2 II of the French Monetary and Financial Code.

This capital increase was executed with institutional investors, including Furui Science Co. (300049:CH), a large Chinese biotech & pharmaceutical group, via its affiliate Furui Medical Science Luxemburg SARL.

Theraclion and its original shareholder Truffle capital now counts on 4 additional major investment funds that would continue to fuel Theraclion's development: Natixis AM and Aviva joined in June 2015 with a private placement followed by Deutsche Bank in December 2015. These three investment funds and Furui now represent nearly 19% of Theraclion shareholder structure.

In connection with the private placement, Theraclion issued 390,000 new shares for a total of €1,770,600 under a capital increase with cancellation of the pre-emptive subscription rights, pursuant to the 17th Resolution approved by the Extraordinary General Meeting of April 28, 2015. The number of these new shares represents 8.09% of the number of shares currently in circulation, which increases the number of shares after the issue to 4,823,272.

The new shares issued will be fungible with existing shares. They will be listed on the Alternext Paris market on the same listing line as existing shares under code ISIN FR0010120402.

Theraclion will use funds from this private placement to grow sales in Europe and develop Echopulse® in existing and new indications. In parallel, Theraclion continues to pursue Echopulse® regulatory approval in the United States and China.

"We are pleased to welcome Furui as a shareholder. It is a key step for Theraclion as we gain traction in Asia. China is our largest market in terms of total benign breast and thyroid tumor procedures performed", says David Caumartin, CEO of Theraclion.

"Furui enters at an inflexion point for us in the region. Strong, early uptake in Hong Kong demonstrates the potential for rapid commercial ramp up." says Sylvain Yon, Deputy CEO and VP Asia of Theraclion.

***This press release may not be distributed in the United States, Canada, Australia or Japan.
This press release is not offering material and is for information purposes only.***



About Theraclion

Theraclion is a French company specializing in high-tech medical equipment using therapeutic ultrasound. Drawing on leading-edge technologies, Theraclion has designed and manufactured an innovative solution for echotherapy, the Echopulse®, allowing non-invasive tumor treatment through ultrasound-guided high-intensity focused ultrasound.

Theraclion is ISO 13485 certified and has received the CE mark for non-invasive ablation of breast fibroadenomas and thyroid nodules. Based in Malakoff, near Paris, France. Theraclion has brought together a team of 34 people, 50 percent of whom are dedicated to R&D and clinical trials. For more information, please visit Theraclion's website: www.theraclion.com.

Theraclion is listed on Alternext Paris.

PEA-PME eligible

Mnemonic: ALTHE - ISIN Code: FR0010120402



Contact:

Theraclion

David Caumartin
Chief Executive Officer
Tel.: +33 (0)1 55 48 90 70
david.caumartin@theraclion.com

NewCap

Financial Communication and Relations
Emmanuel Huynh / Valentine Brouchet
Tel.: +33 (0)1 44 71 94 94
theraclion@newcap.eu

Kalima

Press Relations
Estelle Reine-Adélaïde / Florence Calba
Tel.: + 33 (0)1 44 90 82 54
era@kalima-rp.fr

Disclaimer

This press release and the information it contains does not constitute and shall not be considered as constituting a public offer, an offer to subscribe or an intention to solicit the interest of the public for a public offering of Theraclion securities in France, the United States or any other jurisdiction. In France, the offer of Theraclion shares described above will take place solely as a private placement, in accordance with Article L. 411-2 of the "Code monétaire et financier" and applicable regulations. The offering does not constitute a public offering in France, as defined in Article L. 411-1 of the "Code monétaire et financier" and no prospectus reviewed or approved by the Autorité des marchés financiers will be published.

With respect to Member States of the European Economic Area that have transposed the European Directive 2003/71/EC of the European Parliament and European Council (as amended in particular by Directive 2010/73/EU to the extent that the said Directive has been transposed into each Member State of the European Economic Area), no action has been taken or will be taken to permit a public offering of the securities referred to in this press release requiring the publication of a prospectus in any Member State.

This press release does not constitute and should not be considered to be an offer of securities for sale in the United States. Theraclion does not intend to register securities or conduct a public offering in the United States under the

***This press release may not be distributed in the United States, Canada, Australia or Japan.
This press release is not offering material and is for information purposes only.***



US Securities Act of 1933, as amended. The securities may not be offered or sold in the United States absent registration or an exemption from registration under the US Securities Act of 1933, as amended.

***This press release may not be distributed in the United States, Canada, Australia or Japan.
This press release is not offering material and is for information purposes only.***